Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma

Journal of the National Cancer Institute

Volumn 96, Issue 19, 2004, Pages 1457-1466

  Lindskog, Magnus ^a   Spenger, Christian ^b,c   Jarvet, Jüri ^d   Gräslund, Astrid ^d   Kogner, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CARBENE; CHOLINE; CISPLATIN; ETOPOSIDE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; HYDROCARBON; METHANE; PROTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROBLASTOMA; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANK SUM TEST; RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR CELL LINE; XENOGRAFT; ANIMAL; COMPARATIVE STUDY; DRUG RESISTANCE; EVALUATION; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE RAT; PATHOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; CHOLINE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HYDROCARBONS; MAGNETIC RESONANCE SPECTROSCOPY; MATCHED-PAIR ANALYSIS; METHANE; NEUROBLASTOMA; PREDICTIVE VALUE OF TESTS; PROTONS; RATS; RATS, NUDE; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 5644299741     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh273     Document Type: Article

References (48)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Siegel MJ, Ishwaran H, Fletcher BD, Meyer JS, Hoffer FA, Jaramillo D, et al. Staging of neuroblastoma at imaging: report of the radiology diagnostic oncology group. Radiology 2002;223:168-75.
3. de Certaines JD. High resolution nuclear magnetic resonance spectroscopy in clinical biology: application in oncology. Anticancer Res 1996;16:1325-31.
4. Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000;46:306-18.
5. Burtscher IM, Holtas S. Proton magnetic resonance spectroscopy in brain tumours: clinical applications. Neuroradiology 2001;43:345-52.
6. Maris JM, Evans AE, McLaughlin AC, D'Angio GJ, Bolinger L, Manos H, et al. 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N Engl J Med 1985;312:1500-5.
7. Vaidya SJ, Payne GS, Leach MO, Pinkerton CR. Potential role of magnetic resonance spectroscopy in assessment of tumour response in childhood cancer. Eur J Cancer 2003;39:728-35.
8. Negendank WG, Sauter R, Brown TR, Evelhoch JL, Falini A, Gotsis ED, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996;84:449-58.
9. Wald LL, Nelson SJ, Day MR, Noworolski SE, Henry RG, Huhn SL, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525-34.
10. Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000;18:1020-6.
11. Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, et al. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 1997;89:3778-86.
12. Bezabeh T, Mowat MR, Jarolim L, Greenberg AH, Smith IC. Detection of drug-induced apoptosis and necrosis in human cervical carcinoma cells using (1)H NMR spectroscopy. Cell Death Differ 2001;8:219-224.
13. Cooper WA, Bartier WA, Rideout DC, Delikatny EJ. 1H NMR visible lipids are induce by phosphonium salts and 5-fluorouracil in human breast cancer cells. Magn Reson Med 2001;45:1001-10.
14. Lindskog M, Kogner P, Ponthan F, Schweinhardt P, Sandstedt B, Heiden T, et al. Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (1H MRS). Br J Cancer 2003;88:478-85.
15. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970; 30:2110-8.
16. Biedler JL, Helson L, Spengler BA. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 1973;33:2643-52.
17. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001;61:6185-93.
18. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001;158:2067-77.
19. Zhu X, Wimmer K, Kuick R, Lamb BJ, Motyka S, Jasty R, et al. N-myc modulates expression of p73 in neuroblastoma. Neoplasia 2002;4:432-9.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
21. Blankenberg FG, Storrs RW, Naumovski L, Goralski T, Spielman D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 1996;87:1951-6.
22. Wassberg E, Pahlman S, Westlin JE, Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997;41:327-33.
23. Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, et al. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 1997;89:3778-86.
24. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003;63:2103-8.
25. Ora I, Bondesson L, Jonsson C, Ljungberg J, Porn-Ares I, Garwicz S, et al. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 2000;277:179-85.
26. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999;455:59-62.
27. Karlsson J, Ora I, Porn-Ares I, Pahlman S. Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53. Clin Cancer Res 2004;10:3179-88.
28. Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423-31.
29. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-24.
30. Hayes FA, Green AA, Casper J, Cornet J, Evans WE. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer 1981;48:1715-8.
31. Shafford EA, Rogers DW, Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. J Clin Oncol 1984;2:742-7.
32. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
33. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266: 807-10.
34. Bras-Goncalves RA, Rosty C, Laurent-Puig P, Soulie P, Dutrillaux B, Poupon MF. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 2000;82:913-23.
35. Dijkhuis AJ, Douwes J, Kamps W, Sietsma H, Kok JW. Differential expression of sphingolipids in P-glycoprotein or multidrug resistance-related protein 1 expressing human neuroblastoma cell lines. FEBS Lett 2003;548:28-32.
36. Roman SK, Jeitner TM, Hancock R, Cooper WA, Rideout DC, Delikatny EJ. Induction of magnetic resonance-visible lipid in a transformed human breast cell line by tetraphenylphosphonium chloride. Int J Cancer 1997;73: 570-9.
37. Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat Med 1999;5:1323-7.
38. Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res 2002;62:1394-400.
39. Lehtimaki KK, Valonen PK, Griffin JL, Vaisanen TH, Grohn OH, Kettunen MI, et al. Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro. J Biol Chem 2003;278:45915-23.
40. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001;6:377-88.
41. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003;95:1624-33.
42. Tzika AA, Vajapeyam S, Barnes PD. Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 1997;18:203-18.
43. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 1993; 11:2226-33.
44. Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L, Di Tullio MT, et al. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1993;11:1770-9.
45. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purforst C, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-37.
46. Boccon-Gibod L, Rey A, Sandstedt B, Delemarre J, Harms D, Vujanic G, et al. Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9. Med Pediatr Oncol 2000;34:183-90.
47. Pinkerton CR, Blanc Vincent MP, Bergeron C, Fervers B, Philip T. Induction chemotherapy in metastatic neuroblastoma - does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 2000;36:1808-15.
48. Hahn K, Charron M, Shulkin BL. Role of MR imaging and iodine 123 MIBG scintigraphy in staging of pediatric neuroblastoma. Radiology 2003; 227:908 [author reply 908-9].